Clinical Trials Browser

Phase 2 × Withdrawn × talimogene laherparepvec × Clear all

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Phase 2 Withdrawn

Melanoma, Skin Neoplasms